IRulya Therapeutics Inc.: insider trading
197 trades by 24 directors, officers and 10% owners since 2019, from their SEC Form 4 and 5 filings.
Bought, 12 months
$0
0 purchases by 0 insiders
Sold, 12 months
$174 K
1 sale by 1 insider
Bought, 3 months
$0
0 purchases
Sold, 3 months
$0
0 sales
Insider buying and selling by month
Open-market purchases and sales by value, last three years.
Insiders (24)
Each insider's latest direct holding and their open-market trades of the last 12 months, most recent first.
| Insider | Shares owned directly | Bought, 12 m | Sold, 12 m | Latest trade |
|---|---|---|---|---|
| John MilitelloChief Financial Officer | 80,000 | — | — | |
| Luca BenattiDirector | 39,179 | — | $174 K | |
| Dirk ThyeCEO and CMO, Director | 255,000 | — | — | |
| Brendan HannahCBO, COO & CCO | 361,827 | — | — | |
| Charles S. RyanPresident | 130,009 | — | — | |
| David LamondDirector | 2.30 M | — | — | |
| Margaret McLoughlinDirector | 8,000 | — | — | |
| Ted MonohonChief Accounting Officer & VP | 27,440 | — | — | |
| Caryn Gordon McDowellChief Legal & Adm. Officer | 122,500 | — | — | |
| Leslie HolsingerEVP, Preclinical Development | 148,080 | — | — | |
| Karen L. SmithChief Medical Officer | 194,690 | — | — | |
| Philip S. LowDirector | 455,309 | — | — | |
| Christopher P. LoweInterim CEO, COO & CFO | 265,000 | — | — | |
| Michael J. DetkeChief Medical Officer | 140,000 | — | — | |
| Casey LynchChief Executive Officer, Director | 109,895 | — | — | |
| Stephen S. DominyChief Scientific Officer, Director | — | — | — | |
| Chad BoedingManaging Member of Managing Me | 2.84 M | — | — | |
| Pfizer Strategic Investment Holdings LLC10% owner | 2.88 M | — | — | |
| EPIQ Capital Group, LLCIA/Managing Member of 10% owne | 2.85 M | — | — | |
| Christine Lamond10% owner | — | — | — | |
| Kevin YoungDirector | 30,000 | — | — | |
| Pfizer Ventures (US) LLC10% owner | 3.25 M | — | — | |
| Takeda Pharmaceutical Co LTD10% owner | 2.68 M | — | — | |
| Una S. RyanDirector | — | — | — |
Trades#
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | John MilitelloChief Financial Officer | Grant or award | +80,000 | — | — | 80,000 | Form 4 |
| filed | Luca BenattiDirector | Sell | -50,000 | $3.470 | $174 K | 39,179 | Form 4 |
| filed | Dirk ThyeCEO and CMO, Director | Gift | -739,885 | — | — | 255,000 | Form 4 |
| filed | Dirk ThyeCEO and CMO, Director | Giftindirect | +739,885 | — | — | 739,885 | Form 4 |
| filed | Brendan HannahCBO, COO & CCO | Option exercise | +2,271 | $0.550 | $1 K | 336,547 | Form 4 |
| filed | Brendan HannahCBO, COO & CCO | Option exercise | +25,280 | $0.940 | $24 K | 361,827 | Form 4 |
| filed | Charles S. RyanPresident | Grant or award | +7,548 | $1.200 | $9 K | 130,009 | Form 4 |
| filed | Brendan HannahCBO, COO & CCO | Grant or award | +37,736 | $1.200 | $45 K | 334,276 | Form 4 |
| filed | Dirk ThyeCEO and CMO, Director | Grant or award | +150,944 | $1.200 | $181 K | 994,885 | Form 4 |
| filed | Luca BenattiDirector | Other | +8,918 | — | — | 89,179 | Form 4 |
| filed | Dirk ThyeCEO AND CHIEF MEDICAL OFFICER, Director | Buy | +77,000 | $0.700 | $54 K | 843,941 | Form 4 |
| filed | Dirk ThyeCEO AND CHIEF MEDICAL OFFICER, Director | Buy | +77,500 | $0.690 | $53 K | 766,941 | Form 4 |
| filed | Brendan HannahCHIEF BUSINESS OFFICER AND COO | Buy | +2,280 | $0.610 | $1 K | 267,975 | Form 4 |
| filed | Brendan HannahCHIEF BUSINESS OFFICER AND COO | Buy | +5,000 | $0.620 | $3 K | 272,975 | Form 4 |
| filed | Brendan HannahCHIEF BUSINESS OFFICER AND COO | Buy | +23,565 | $0.630 | $15 K | 296,540 | Form 4 |
| filed | Charles S. RyanPRESIDENT | Buy | +48,387 | $0.650 | $31 K | 122,461 | Form 4 |
| filed | Brendan HannahCHIEF BUSINESS OFFICER AND COO | Buy | +2,500 | $0.610 | $2 K | 262,271 | Form 4 |
| filed | Brendan HannahCHIEF BUSINESS OFFICER AND COO | Buy | +3,424 | $0.600 | $2 K | 265,695 | Form 4 |
| filed | Brendan HannahCHIEF BUSINESS OFFICER AND COO | Buy | +2,155 | $0.580 | $1 K | 259,771 | Form 4 |
| filed | Brendan HannahCHIEF BUSINESS OFFICER AND COO | Option exercise | +56,061 | $0.550 | $31 K | 257,616 | Form 4 |
| filed | Dirk ThyeCHIEF EXECUTIVE OFFICER, Director | Option exercise | +90,531 | $0.550 | $50 K | 539,442 | Form 4 |
| filed | Dirk ThyeCHIEF EXECUTIVE OFFICER, Director | Option exercise | +149,999 | $0.940 | $141 K | 689,441 | Form 4 |
| filed | David LamondDirector | Buyindirect | +22,627 | $1.040 | $24 K | 2.35 M | Form 4 |
| filed | David LamondDirector | Buyindirect | +22,627 | $1.000 | $23 K | 2.32 M | Form 4 |
| filed | David LamondDirector | Buyindirect | +300 | $1.000 | $300 | 2.28 M | Form 4 |
| filed | David LamondDirector | Buy | +22,327 | $1.020 | $23 K | 2.30 M | Form 4 |
| filed | David LamondDirector | Buyindirect | +19,123 | $1.010 | $19 K | 2.28 M | Form 4 |
| filed | David LamondDirector | Buyindirect | +19,123 | $1.020 | $20 K | 2.26 M | Form 4 |
| filed | David LamondDirector | Buyindirect | +19,123 | $1.010 | $19 K | 2.24 M | Form 4 |
| filed | David LamondDirector | Buyindirect | +14,378 | $0.940 | $14 K | 2.22 M | Form 4 |
| filed | David LamondDirector | Buyindirect | +14,378 | $0.900 | $13 K | 2.21 M | Form 4 |
| filed | David LamondDirector | Buyindirect | +14,378 | $0.980 | $14 K | 2.19 M | Form 4 |
| filed | David LamondDirector | Buyindirect | +41,026 | $1.320 | $54 K | 2.18 M | Form 4 |
| filed | David LamondDirector | Buyindirect | +41,026 | $1.310 | $54 K | 2.14 M | Form 4 |
| filed | David LamondDirector | Buyindirect | +24,766 | $1.290 | $32 K | 2.10 M | Form 4 |
| filed | David LamondDirector | Buyindirect | +117,348 | $1.290 | $151 K | 2.07 M | Form 4 |
| filed | David LamondDirector | Buyindirect | +107,886 | $1.320 | $142 K | 1.95 M | Form 4 |
| filed | Dirk ThyeChief Executive Officer, Director | Buy | +88,000 | $1.260 | $111 K | 448,911 | Form 4 |
| filed | Brendan HannahChief Business Officer | Buy | +71,762 | $1.220 | $88 K | 201,555 | Form 4 |
| filed | Dirk ThyeChief Executive Officer, Director | Buy | +80,000 | $1.240 | $99 K | 360,911 | Form 4 |
| filed | Margaret McLoughlinDirector | Buy | +8,000 | $1.230 | $10 K | 8,000 | Form 4 |
| filed | Ted MonohonChief Accounting Officer & VP | Sell10b5-1 plan | -1,871 | $0.980 | $2 K | 27,440 | Form 4 |
| filed | Ted MonohonChief Accounting Officer & VP | Shares withheld for tax10b5-1 plan | -1,640 | $0.720 | $1 K | 29,311 | Form 4 |
| filed | Ted MonohonChief Accounting Officer & VP | Shares withheld for tax10b5-1 plan | -1,520 | $1.640 | $2 K | 30,951 | Form 4 |
| filed | Leslie HolsingerEVP, Preclinical Development | Shares withheld for tax10b5-1 plan | -10,920 | $2.860 | $31 K | 148,080 | Form 4 |
| filed | Ted MonohonChief Accounting Officer & VP | Shares withheld for tax10b5-1 plan | -1,529 | $3.120 | $5 K | 32,471 | Form 4 |
| filed | Caryn Gordon McDowellChief Legal & Adm. Officer | Shares withheld for tax10b5-1 plan | -6,700 | $2.860 | $19 K | 133,300 | Form 4 |
| filed | Caryn Gordon McDowellChief Legal & Adm. Officer | Sell | -10,800 | $2.860 | $31 K | 122,500 | Form 4 |
| filed | Brendan HannahChief Business Officer | Grant or awardamended | +113,569 | — | — | 129,793 | Form 4/A |
| filed | Dirk ThyeChief Executive Officer, Director | Grant or awardamended | +216,322 | — | — | 280,911 | Form 4/A |
| filed | Karen L. SmithChief Medical Officer | Grant or awardamended | +170,354 | — | — | 194,690 | Form 4/A |
| filed | Dirk ThyeChief Executive Officer, Director | Grant or award | +64,589 | — | — | 64,589 | Form 4 |
| filed | Karen L. SmithChief Medical Officer | Grant or award | +24,336 | — | — | 24,336 | Form 4 |
| filed | Brendan HannahChief Business Officer | Grant or award | +16,224 | — | — | 16,224 | Form 4 |
| filed | Philip S. LowDirector | Grant or award | +455,309 | — | — | 455,309 | Form 4 |
| filed | David LamondDirector | Grant or awardindirect | +200,002 | — | — | 1.73 M | Form 4 |
| filed | Philip S. LowDirector | Grant or awardindirect | +63,974 | — | — | 63,974 | Form 4 |
| filed | Leslie HolsingerEVP, Preclinical Development | Grant or award | +155,500 | — | — | 159,000 | Form 4 |
| filed | Caryn Gordon McDowellChief Legal & Adm. Officer | Grant or award | +140,000 | — | — | 140,000 | Form 4 |
| filed | Ted MonohonChief Accounting Officer & VP | Grant or award | +34,000 | — | — | 34,000 | Form 4 |
| filed | Michael J. DetkeChief Medical Officer | Grant or award | +140,000 | — | — | 140,000 | Form 4 |
| filed | Christopher P. LoweInterim CEO, COO & CFO | Grant or award | +175,000 | — | — | 265,000 | Form 4 |
| filed | Casey LynchChief Executive Officer, Director | Option exercise | +60,000 | $0.460 | — | 109,895 | Form 4 |
| filed | Christopher P. LoweCOO & Chief Financial Officer | Option exercise | +30,000 | $2.230 | — | 90,000 | Form 4 |
| filed | Stephen S. DominyChief Scientific Officer, Director | Buyindirect | +763 | $14.40 | $11 K | 1.22 M | Form 4 |
| filed | Margaret McLoughlinDirector | Option exercise | +1,000 | $17.00 | $17 K | 1,000 | Form 4 |
| filed | Margaret McLoughlinDirector | Sell10b5-1 plan | -1,000 | $88.93 | $89 K | 0 | Form 4 |
| filed | Christopher P. LoweCOO & Chief Financial Officer | Option exercise | +4,963 | $54.85 | $272 K | 64,963 | Form 4 |
| filed | Christopher P. LoweCOO & Chief Financial Officer | Sell10b5-1 plan | -4,963 | $98.50 | $489 K | 60,000 | Form 4 |
| filed | Christopher P. LoweCOO & Chief Financial Officer | Option exercise | +30,000 | $2.230 | — | 60,000 | Form 4 |
| filed | Margaret McLoughlinDirector | Option exercise | +6,000 | $17.00 | $102 K | 6,000 | Form 4 |
| filed | Christopher P. LoweCOO & Chief Financial Officer | Option exercise | +22,000 | $2.230 | — | 52,000 | Form 4 |
| filed | Christopher P. LoweCOO & Chief Financial Officer | Sell10b5-1 plan | -9,158 | $94.23 | $863 K | 42,842 | Form 4 |
| filed | Margaret McLoughlinDirector | Sell10b5-1 plan | -3,056 | $94.55 | $289 K | 2,944 | Form 4 |
| filed | Christopher P. LoweCOO & Chief Financial Officer | Sell10b5-1 plan | -7,335 | $95.02 | $697 K | 35,507 | Form 4 |
| filed | Margaret McLoughlinDirector | Sell10b5-1 plan | -1,044 | $95.57 | $100 K | 1,900 | Form 4 |
| filed | Christopher P. LoweCOO & Chief Financial Officer | Sell10b5-1 plan | -2,330 | $96.32 | $224 K | 33,177 | Form 4 |
| filed | Margaret McLoughlinDirector | Sell10b5-1 plan | -1,429 | $96.51 | $138 K | 471 | Form 4 |
| filed | Christopher P. LoweCOO & Chief Financial Officer | Sell10b5-1 plan | -1,100 | $97.28 | $107 K | 32,077 | Form 4 |
| filed | Margaret McLoughlinDirector | Sell10b5-1 plan | -423 | $97.55 | $41 K | 48 | Form 4 |
| filed | Margaret McLoughlinDirector | Sell10b5-1 plan | -48 | $98.90 | $5 K | 0 | Form 4 |
| filed | Christopher P. LoweCOO & Chief Financial Officer | Sell10b5-1 plan | -2,077 | $98.90 | $205 K | 30,000 | Form 4 |
| filed | Michael J. DetkeChief Medical Officer | Option exercise | +10,000 | $2.230 | — | 10,000 | Form 4 |
| filed | Michael J. DetkeChief Medical Officer | Sell10b5-1 plan | -10,000 | $100.00 | $1.0 M | 0 | Form 4 |
| filed | Michael J. DetkeChief Medical Officer | Option exercise | +17,400 | $2.230 | — | 17,400 | Form 4 |
| filed | Michael J. DetkeChief Medical Officer | Sell10b5-1 plan | -3,934 | $53.24 | $209 K | 13,466 | Form 4 |
| filed | Michael J. DetkeChief Medical Officer | Sell10b5-1 plan | -1,648 | $54.37 | $90 K | 11,818 | Form 4 |
| filed | Michael J. DetkeChief Medical Officer | Sell10b5-1 plan | -4,353 | $55.38 | $241 K | 7,465 | Form 4 |
| filed | Michael J. DetkeChief Medical Officer | Sell10b5-1 plan | -6,942 | $56.27 | $391 K | 523 | Form 4 |
| filed | Michael J. DetkeChief Medical Officer | Sell10b5-1 plan | -523 | $56.99 | $30 K | 0 | Form 4 |
| filed | Michael J. DetkeChief Medical Officer | Option exercise | +12,600 | $2.230 | — | 40,861 | Form 4 |
| filed | Michael J. DetkeChief Medical Officer | Sell10b5-1 plan | -32,313 | $53.43 | $1.7 M | 8,548 | Form 4 |
| filed | Michael J. DetkeChief Medical Officer | Sell10b5-1 plan | -8,260 | $53.91 | $445 K | 288 | Form 4 |
| filed | Michael J. DetkeChief Medical Officer | Sell10b5-1 plan | -288 | $55.01 | $16 K | 0 | Form 4 |
| filed | Christopher P. LoweCOO & Chief Financial Officer | Option exercise | +30,000 | $2.230 | — | 30,000 | Form 4 |
| filed | Christopher P. LoweCOO & Chief Financial Officer | Option exercise | +20,000 | $2.230 | — | 20,000 | Form 4 |
| filed | Christopher P. LoweCOO & Chief Financial Officer | Sell10b5-1 plan | -7,724 | $53.39 | $412 K | 12,276 | Form 4 |
| filed | Christopher P. LoweCOO & Chief Financial Officer | Sell10b5-1 plan | -7,079 | $54.13 | $383 K | 5,197 | Form 4 |
| filed | Christopher P. LoweCOO & Chief Financial Officer | Sell10b5-1 plan | -4,153 | $55.11 | $229 K | 1,044 | Form 4 |
| filed | Christopher P. LoweCOO & Chief Financial Officer | Sell10b5-1 plan | -1,044 | $56.16 | $59 K | 0 | Form 4 |
| filed | Margaret McLoughlinDirector | Sell10b5-1 plan | -200 | $55.01 | $11 K | 350 | Form 4 |
| filed | Margaret McLoughlinDirector | Sell10b5-1 plan | -250 | $55.03 | $14 K | 100 | Form 4 |
| filed | Margaret McLoughlinDirector | Sell10b5-1 plan | -100 | $55.73 | $6 K | 0 | Form 4 |
| filed | Casey LynchChief Executive Officer, Director | Sell10b5-1 plan · indirect | -13,584 | $33.75 | $458 K | 995,190 | Form 4 |
| filed | Casey LynchChief Executive Officer, Director | Sell10b5-1 plan · indirect | -9,918 | $34.89 | $346 K | 985,272 | Form 4 |
| filed | Casey LynchChief Executive Officer, Director | Sell10b5-1 plan · indirect | -6,315 | $35.81 | $226 K | 978,957 | Form 4 |
| filed | Casey LynchChief Executive Officer, Director | Sell10b5-1 plan · indirect | -183 | $36.73 | $7 K | 978,774 | Form 4 |
| filed | David LamondDirector | Buyindirect | +50,000 | $33.77 | $1.7 M | 1.85 M | Form 4 |
| filed | Casey LynchChief Executive Officer, Director | Sell10b5-1 plan · indirect | -11,211 | $35.10 | $394 K | 1.03 M | Form 4 |
| filed | Casey LynchChief Executive Officer, Director | Sell10b5-1 plan · indirect | -18,089 | $35.85 | $648 K | 1.01 M | Form 4 |
| filed | Casey LynchChief Executive Officer, Director | Sell10b5-1 plan · indirect | -300 | $36.58 | $11 K | 1.01 M | Form 4 |
| filed | Casey LynchChief Executive Officer, Director | Sell10b5-1 plan · indirect | -400 | $36.60 | $15 K | 1.01 M | Form 4 |
| filed | David LamondDirector | Giftindirect | +1.53 M | — | — | 1.53 M | Form 4 |
| filed | David LamondDirector | Buyindirect | +16,621 | $34.28 | $570 K | 1.76 M | Form 4 |
| filed | David LamondDirector | Buyindirect | +13,310 | $35.00 | $466 K | 1.78 M | Form 4 |
| filed | David LamondDirector | Buyindirect | +15,969 | $36.34 | $580 K | 1.79 M | Form 4 |
| filed | David LamondDirector | Buyindirect | +4,100 | $36.86 | $151 K | 1.80 M | Form 4 |
| filed | Casey LynchChief Executive Officer, Director | Sell10b5-1 plan · indirect | -400 | $37.39 | $15 K | 1.06 M | Form 4 |
| filed | Casey LynchChief Executive Officer, Director | Sell10b5-1 plan · indirect | -1,600 | $38.64 | $62 K | 1.06 M | Form 4 |
| filed | Casey LynchChief Executive Officer, Director | Sell10b5-1 plan · indirect | -856 | $39.82 | $34 K | 1.06 M | Form 4 |
| filed | Casey LynchChief Executive Officer, Director | Sell10b5-1 plan · indirect | -2,000 | $40.84 | $82 K | 1.05 M | Form 4 |
| filed | Casey LynchChief Executive Officer, Director | Sell10b5-1 plan · indirect | -3,100 | $41.91 | $130 K | 1.05 M | Form 4 |
| filed | Casey LynchChief Executive Officer, Director | Sell10b5-1 plan · indirect | -1,512 | $43.10 | $65 K | 1.05 M | Form 4 |
| filed | Casey LynchChief Executive Officer, Director | Sell10b5-1 plan · indirect | -1,900 | $44.22 | $84 K | 1.05 M | Form 4 |
| filed | Casey LynchChief Executive Officer, Director | Sell10b5-1 plan · indirect | -8,032 | $45.00 | $361 K | 1.04 M | Form 4 |
| filed | Casey LynchChief Executive Officer, Director | Sell10b5-1 plan · indirect | -600 | $45.73 | $27 K | 1.04 M | Form 4 |
| filed | Casey LynchChief Executive Officer, Director | Sell10b5-1 plan · indirect | -14,929 | $36.02 | $538 K | 1.06 M | Form 4 |
| filed | Casey LynchChief Executive Officer, Director | Sell10b5-1 plan · indirect | -5,071 | $36.75 | $186 K | 1.06 M | Form 4 |
| filed | Casey LynchChief Executive Officer, Director | Sell10b5-1 plan · indirect | -4,686 | $34.60 | $162 K | 1.09 M | Form 4 |
| filed | Casey LynchChief Executive Officer, Director | Sell10b5-1 plan · indirect | -3,100 | $35.59 | $110 K | 1.09 M | Form 4 |
| filed | Casey LynchChief Executive Officer, Director | Sell10b5-1 plan · indirect | -7,460 | $36.56 | $273 K | 1.08 M | Form 4 |
| filed | Casey LynchChief Executive Officer, Director | Sell10b5-1 plan · indirect | -4,283 | $37.68 | $161 K | 1.08 M | Form 4 |
| filed | Casey LynchChief Executive Officer, Director | Sell10b5-1 plan · indirect | -100 | $38.28 | $4 K | 1.08 M | Form 4 |
| filed | Casey LynchChief Executive Officer, Director | Sell10b5-1 plan · indirect | -371 | $39.23 | $15 K | 1.08 M | Form 4 |
| filed | Leslie HolsingerExecutive Vice President | Option exercise | +40,000 | $0.270 | — | 43,500 | Form 4 |
| filed | Leslie HolsingerExecutive Vice President | Sell10b5-1 plan | -1,700 | $28.80 | $49 K | 41,800 | Form 4 |
| filed | Leslie HolsingerExecutive Vice President | Sell10b5-1 plan | -14,275 | $30.15 | $430 K | 27,525 | Form 4 |
| filed | Leslie HolsingerExecutive Vice President | Sell10b5-1 plan | -13,200 | $30.91 | $408 K | 14,325 | Form 4 |
| filed | Leslie HolsingerExecutive Vice President | Sell10b5-1 plan | -9,525 | $31.79 | $303 K | 1,800 | Form 4 |
| filed | Leslie HolsingerExecutive Vice President | Sell10b5-1 plan | -400 | $32.59 | $13 K | 4,400 | Form 4 |
| filed | Leslie HolsingerExecutive Vice President | Sell10b5-1 plan | -900 | $32.59 | $29 K | 3,500 | Form 4 |
| filed | Leslie HolsingerExecutive Vice President | Option exercise | +3,500 | $0.270 | — | 3,500 | Form 4 |
| filed | Chad BoedingManaging Member of Managing Me | Buyindirect | +2,440 | $44.06 | $108 K | 2.86 M | Form 4 |
| filed | Chad BoedingManaging Member of Managing Me | Buyindirect | +6,600 | $44.32 | $293 K | 2.86 M | Form 4 |
| filed | David LamondDirector | Buyindirect | +13,609 | $42.13 | $573 K | 1.71 M | Form 4 |
| filed | David LamondDirector | Buyindirect | +10,642 | $43.32 | $461 K | 1.72 M | Form 4 |
| filed | David LamondDirector | Buyindirect | +24,874 | $43.88 | $1.1 M | 1.75 M | Form 4 |
| filed | Pfizer Strategic Investment Holdings LLC10% owner | Sell | -370,000 | $40.18 | $14.9 M | 2.88 M | Form 4 |
| filed | Michael J. DetkeChief Medical Officer | Option exercise | +5,515 | $6.910 | $38 K | 28,261 | Form 4 |
| filed | Chad BoedingManaging Member of 10% Owner | Buyindirect | +2,085 | $55.90 | $117 K | 2.85 M | Form 4 |
| filed | Chad BoedingManaging Member of 10% Owner | Buyindirect | +520 | $55.80 | $29 K | 2.85 M | Form 4 |
| filed | Chad BoedingManaging Member of 10% Owner | Buyindirect | +5,668 | $58.00 | $329 K | 2.85 M | Form 4 |
| filed | Chad BoedingManaging Member of 10% Owner | Buyindirect | +417 | $57.22 | $24 K | 2.85 M | Form 4 |
| filed | David LamondDirector | Buyindirect | +400 | $54.09 | $22 K | 1.66 M | Form 4 |
| filed | David LamondDirector | Buyindirect | +5,906 | $55.42 | $327 K | 1.67 M | Form 4 |
| filed | David LamondDirector | Buyindirect | +32,894 | $56.42 | $1.9 M | 1.70 M | Form 4 |
| filed | David LamondDirector | Buyindirect | +1,263 | $46.30 | $58 K | 1.65 M | Form 4 |
| filed | David LamondDirector | Buyindirect | +985 | $48.37 | $48 K | 1.66 M | Form 4 |
| filed | David LamondDirector | Buyindirect | +1,600 | $48.96 | $78 K | 1.66 M | Form 4 |
| filed | David LamondDirector | Buyindirect | +1,000 | $50.71 | $51 K | 1.66 M | Form 4 |
| filed | David LamondDirector | Buyindirect | +500 | $52.20 | $26 K | 1.66 M | Form 4 |
| filed | David LamondDirector | Buyindirect | +100 | $53.10 | $5 K | 1.66 M | Form 4 |
| filed | Michael J. DetkeChief Medical Officer | Option exercise | +5,515 | $6.910 | $38 K | 22,746 | Form 4 |
| filed | David LamondDirector | Grant or awardindirect | +30,000 | $50.00 | $1.5 M | 1.65 M | Form 4 |
| filed | Michael J. DetkeChief Medical Officer | Option exercise | +17,231 | $6.910 | $119 K | 17,231 | Form 4 |
| filed | Chad BoedingManaging Member of Managing Me | Otherindirect | -4,338 | $54.30 | $236 K | 2.84 M | Form 4 |
| filed | EPIQ Capital Group, LLCIA/Managing Member of 10% owne | Buyindirect · amended | +420 | $24.87 | $10 K | 2.85 M | Form 4/A |
| filed | EPIQ Capital Group, LLCIA/Managing Member of 10% owne | Buyamended | +1,635 | $24.87 | $41 K | 2.85 M | Form 4/A |
| filed | EPIQ Capital Group, LLCIA/Managing Member 10% owner | Buyindirect | +420 | $24.87 | $10 K | 2.83 M | Form 4 |
| filed | EPIQ Capital Group, LLCIA/Managing Member 10% owner | Buy | +1,635 | $24.87 | $41 K | 2.83 M | Form 4 |
| filed | EPIQ Capital Group, LLCIA/Managing Member of 10% owne | Buyindirect · amended | +600 | $25.69 | $15 K | 2.84 M | Form 4/A |
| filed | EPIQ Capital Group, LLCIA/Managing Member of 10% owne | Buyamended | +2,310 | $25.69 | $59 K | 2.85 M | Form 4/A |
| filed | EPIQ Capital Group, LLCIA/Managing Member 10% owner | Buyindirect | +600 | $25.69 | $15 K | 2.83 M | Form 4 |
| filed | EPIQ Capital Group, LLCIA/Managing Member 10% owner | Buy | +2,310 | $25.69 | $59 K | 2.83 M | Form 4 |
| filed | EPIQ Capital Group, LLCIA/Managing Member of 10% owne | Buyindirect · amended | +2,100 | $26.50 | — | 2.84 M | Form 4/A |
| filed | Chad BoedingManaging Member of IA | Buyindirect | +2,100 | $26.50 | $56 K | 2.83 M | Form 4 |
| filed | EPIQ Capital Group, LLCIA/Managing Member of 10% owne | Buyindirect · amended | +700 | $26.37 | — | 2.84 M | Form 4/A |
| filed | Chad BoedingManaging Member of IA | Buyindirect | +700 | $26.37 | $18 K | 2.83 M | Form 4 |
| filed | Margaret McLoughlinDirector | Buy | +550 | $17.00 | $9 K | 550 | Form 4 |
| filed | Una S. RyanDirector | Buyindirect | +2,875 | $17.00 | $49 K | 2,875 | Form 4 |
| filed | Kevin YoungDirector | Buy | +30,000 | $17.00 | $510 K | 30,000 | Form 4 |
| filed | Pfizer Ventures (US) LLC10% owner | Conversion | +2.36 M | — | — | 2.36 M | Form 4 |
| filed | Pfizer Ventures (US) LLC10% owner | Conversion | +215,697 | — | — | 2.58 M | Form 4 |
| filed | Pfizer Ventures (US) LLC10% owner | Conversion | +624,205 | — | — | 3.20 M | Form 4 |
| filed | Pfizer Ventures (US) LLC10% owner | Buy | +50,000 | $17.00 | $850 K | 3.25 M | Form 4 |
| filed | David LamondDirector | Conversionindirect | +1.62 M | — | — | 1.62 M | Form 4 |
| filed | Takeda Pharmaceutical Co LTD10% owner | Conversion | +2.68 M | — | — | 2.68 M | Form 4 |
| filed | Christine Lamond10% owner | Conversionindirect | +962,510 | — | — | 962,510 | Form 4 |
| filed | Christine Lamond10% owner | Conversionindirect | +962,510 | — | — | 962,510 | Form 4 |
| filed | David LamondDirector | Conversion | +301,829 | — | — | 301,829 | Form 4 |
| filed | Christine Lamond10% owner | Conversionindirect | +961,510 | — | — | 961,510 | Form 4 |
| filed | Chad BoedingManaging Member of Managing Me | Buyamended | +4,350 | $26.41 | — | 2.84 M | Form 4/A |
| filed | Chad BoedingManaging Member of Managing Me | Buyindirect · amended | +4,170 | $27.58 | — | 2.84 M | Form 4/A |
| filed | Chad BoedingManaging Member of Managing Me | Buyindirect · amended | +80 | $27.05 | — | 2.84 M | Form 4/A |
| filed | EPIQ Capital Group, LLCIA/Managing Member 10% owner | Buy | +4,350 | $26.41 | $115 K | 2.82 M | Form 4 |
| filed | EPIQ Capital Group, LLCIA/Managing Member 10% owner | Buyindirect | +4,170 | $27.58 | $115 K | 2.83 M | Form 4 |
| filed | EPIQ Capital Group, LLCIA/Managing Member 10% owner | Buyindirect | +80 | $27.05 | $2 K | 2.83 M | Form 4 |
Source: SEC Forms 4 and 5. A trade under a 10b5-1 plan was scheduled in advance. For information only; not investment advice